Approval · Notice of Compliance 1764 · 1999
INTEGRILIN: Notice of Compliance 1764
Issued June 11, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1764
- Date
- June 11, 1999
- Company
- Cor Therapeutics, Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INTEGRILIN | 02240352 | Cancelled Post Market |
| INTEGRILIN | 02240351 | Cancelled Post Market |
Medicinal ingredients
- EPTIFIBATIDE 2 MG per ML
- EPTIFIBATIDE 0.75 MG per ML